H. Lundbeck A/S (0ABR)
London Exchange · UK · prices in DKK · close of 23 Oct 2026
Key indicators
| Last close | DKK 49.25 |
|---|---|
| 52-week range | 31.60 – 49.25 |
| Return, 1 month / 3 months | +18.0% / +35.7% |
| Return, 1 year / 3 years | +41.9% / +73.1% |
| Trend | Uptrend |
| RSI (14) | 77 |
| Volatility (1 year) | 29.4% |
| Worst drawdown (1 year) | -16.8% |
| Average daily value traded | 2.01M DKK |
| Dividend yield | 2.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
H. Lundbeck A/S is a pharmaceutical company based in Copenhagen, Denmark, that focuses on medicines for disorders of the brain. It develops and markets prescription treatments for conditions such as depression, schizophrenia, Alzheimer's disease and Parkinson's disease. Its customers are mainly doctors, hospitals and healthcare systems, and its products are used in many countries. The company also carries out research into new therapies for psychiatric and neurological illness.
On this site H. Lundbeck A/S appears as a stock on the London Exchange (UK), code 0ABR, with prices in Danish kroner (DKK). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
H. Lundbeck A/S (0ABR) trades on the London Exchange in UK. It last closed at DKK 49.25 on 23 October 2026.
Its price-based Market X-Ray is 74 out of 100 (a strong price profile), ranking 286 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 41.9% and over the last three months it rose 35.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 93 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 33.0% | ||
| From 52-week high | 0.0% | ||
| Momentum | 86 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 35.7% | ||
| 6-month return | 41.5% | ||
| 12-month return, skipping the last month | 20.3% | ||
| Stability (higher is calmer) | 73 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 29.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -16.8% | ||
| Liquidity | 60 · Fair | Moderate trading activity. | |
| Average daily value traded | 2.01M DKK | ||
| Zero-volume days | 13.3% | ||
| Income | 25 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.3% | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +8.3% |
|---|---|
| 1 month | +18.0% |
| 3 months | +35.7% |
| 6 months | +41.5% |
| 1 year | +41.9% |
| 3 years | +73.1% |
| 5 years | – |
Signals
| 50-day / 200-day average | 42.17 / 37.02 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.94 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 19 Mar 2026 | DKK 1.1500 |
| 27 Mar 2025 | DKK 0.9500 |
| 21 Mar 2024 | DKK 0.7000 |
| 22 Mar 2023 | DKK 0.5800 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.